SCHEMBL26985184

SCHEMBL26985184

CSc1nccc(Cc2cncc(Nc3ccc(Br)cc3F)c2C)c1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ TP53 P04637 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RET P07949 2/20 0.32
▸ EGFR P00533 1/20 0.32
▸ KIF5B P33176 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ DYRK1A Q13627 2/20 0.31
▸ DYRK1B Q9Y463 1/20 0.31
▸ MAP2K1 Q02750 3/20 0.31
▸ MAP2K2 P36507 2/20 0.30
▸ ABCB11 O95342 1/20 0.30
▸ NQO2 P16083 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ HDAC3 O15379 1/20 0.30
▸ HDAC1 Q13547 1/20 0.30
▸ HDAC6 Q9UBN7 1/20 0.30
▸ NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746457 1.00 CLK1 (0.34) CLK1MAPK1TP53MAPTRET
SCHEMBL30746541 0.90 SHMT2 (0.32) MAPK1MAPTGAAL3MBTL1KMT2A
SCHEMBL26984874 0.90 SHMT2 (0.32) MAPK1MAPTGAAL3MBTL1KMT2A
SCHEMBL30746438 0.88 NUDT1 (0.41) EGFRKDRKMT2A
SCHEMBL26984916 0.88 NUDT1 (0.41) EGFRKDRKMT2A
SCHEMBL26984845 0.86 MAPK1 (0.35) CLK1MAPK1TP53MAPTRET
SCHEMBL30746672 0.86 MAPK1 (0.35) CLK1MAPK1TP53MAPTRET
SCHEMBL30746469 0.83 KMT2A (0.34) CLK1MAPK1TP53MAPTRET
SCHEMBL26984886 0.83 KMT2A (0.34) CLK1MAPK1TP53MAPTRET
SCHEMBL26994476 0.82 CLK1 (0.33) CLK1MAPK1TP53MAPTRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 CLK1 295/4885MAPK1 3/4885TP53 3602/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 CLK1 458/4885MAPK1 9/4885TP53 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback